amiridine and Cognition-Disorders

Clinical, neuropsychological and neurophysiological examination was performed in 53 patients, aged 33-75 years, in the early rehabilitation period of the first hemispheric ischemic stroke. Cognitive functions were measured with the MMSE, the FAB, the Clock Drawing Test, the 5-Word test, the Schulte probe, verbal fluency test, etc. Cognitive evoked potentials were recorded in 30 patients. Examination was carried out a month after the stroke and after 2 months of therapy with neuromidin (ipidacrinum). The control group consisted of 37 people without stroke in the case history. The statistically significant decrease of cognitive functions in comparison with control group was revealed at the first visit. The statistically significant regression of cognitive deficit, with the most distinct positive dynamics of frontal functions and semantic verbal fluency, was identified as a result of the treatment. The significant improvement in cognitive evoked potentials in the form of the reduction of P3 latency was recorded after the treatment.

Topics: Adult; Aged; Aminoquinolines; Brain Ischemia; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Electroencephalography; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Male; Middle Aged; Neuropsychological Tests; Time Factors; Treatment Outcome

To evaluate the efficacy and safety of neyromidin in the treatment of Stage I hypertensive dyscirculatory encephalopathy (HDE) and to analyze long-term treatment results.. Fifty-seven with Stage I dyscirculatory encephalopathy in the presence of grades 1-2 arterial hypertension were examined. Clinical, psychological, and electrophysiological studies were performed and the efficacy of neyromidin was evaluated using the SANDOS geriatric scale. Neyromidin as monotherapy was used as one tablet (20 mg) b.i.d. during a meal. The duration of course treatment was 3 months.. Positive changes in the early manifestations of HDE were observed just on day 45 of therapy. The therapeutic effect of the drug manifested as a reduction in the degree of clinical symptoms. There were positive changes in attention, memory, kinetics, verbal associations, counting. The most noticeable improvement was seen in the values of memory and intellectual processes, suggesting higher working capacity, reduced fatigability, and eliminated sluggishness of intellectual processes. EEG displayed a higher amplitude level, a better response to rhythmic photostimulation, and a total power rise in a- and 8-ranges, which was indicative of the activated effect of neyromidin on the functional state of brain structures.. Neyromidin (20 mg b.i.d. for 3 months) was shown to be effective and well tolerated. The drug reduced the magnitude of clinical manifestations and improved psychological functions and electrophysiological parameters.

Topics: Aminoquinolines; Brain; Cholinesterase Inhibitors; Cognition Disorders; Electroencephalography; Female; Humans; Hypertension; Hypertensive Encephalopathy; Male; Middle Aged; Neuropsychological Tests; Severity of Illness Index; Treatment Outcome

Efficacy of neuromidin was studied in 62 patients with a small ischemic stroke and cognitive disorders. Patients of the main group received neuromidin as an add-on to basic treatment and patients of the comparison group received only basic treatment (antiaggregant, antihypertensive, cardiac and antidiabetic drugs with the exclusion of nootropic and psychotropic medications). The decrease of subjective complaints, improvement of memory, attention, abstract and practical reasoning assessed by neuropsychological tests were seen in 32 patients of the main group after the end of treatment course. Neuromidin did not cause side-effects and was well tolerated. The long use of this led to the reduction of cognitive impairment, a predictor of vascular dementia.

Topics: Adult; Aged; Aminoquinolines; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Stroke

The efficacy and safety of axamon was studied in a trial with parallel groups in patients, aged 65-88 years, with movement and cognitive disorders in the residual period of stroke. Twenty-five patients received basic therapy and 25 patients were treated with axamon as an add-on drug in dosage of 20 mg 3 times a day during 12 weeks. Along with the neurological examination, a battery of neuropsychological scales and tests was used. The reduction of cognitive and movement deficits was observed. Axamon promotes the optimization of restoration potential of patients in the residual period of stroke.

Topics: Aged; Aged, 80 and over; Aminoquinolines; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Male; Motor Activity; Paresis; Stroke; Treatment Outcome

An objective of the study was to investigate the effectiveness of neuromidin in stable schizophrenic patients with predominance of symptoms of pseudoorganic deficits. Fifty-five patients stable after a transition from routine medication to monotherapy with risperidone were randomized into two groups with add-on placebo or neuromidin treatment. Patients were studied during 24 weeks. The PANSS and a battery of neurocognitive tests were used for assessment of treatment. In the end of the trial, positive changes on the following PANSS items - N1, N2, N6, N7, G4, G7 and G13 were observed in the neuromidin group. In the placebo group, the changes were found only on one PANSS item - N2. The decrease of scores on this item (emotional withdrawal) during the study was more significant only in the patients receiving neuromidin (p=0,037). The results of assessment of cognitive functioning showed the positive changes in visual-spatial memory, attention, retention and retrieval of data, planning in the group treated with neuromidin. In the placebo group, the positive changes were observed only in one index - one type of mistakes (omissions) in visual-spatial memory test. In the end of the trial, between-group differences were significant for planning - number of tasks with time-limit violation and rule violations. All differences were beneficial for patients treated with neuromidin. Not all tests were sensitive to changes in cognitive status of patients: indices of working memory, psychomotor speed, flexibility of attention were not changed significantly in both groups, nor they changed between groups. The authors conclude that the problem of rationality of add-on anticholinergic treatment in schizophrenia is not solved yet due to the difficulties in selection of patients and tests for cognitive assessment. The need of further studies is emphasized.

Topics: Aminoquinolines; Antipsychotic Agents; Brain; Cholinesterase Inhibitors; Cognition Disorders; Drug Therapy, Combination; Humans; Neuropsychological Tests; Potassium; Risperidone; Schizophrenia; Severity of Illness Index

The paper presents a study concerning an influence of cerebrolysin on the efficiency of subsequent therapy with amiridin in patients with mild and moderate dementia of Altzheimer's type (DAT). A study included 2 groups of patients similar in terms of clinical and demographic parameters. The patients of group 1 (23 cases) were treated by amiridin in daily dose of 80 mg during 10 weeks. In group 2 (26 patients) a session of 20 intravenous infusions of cerebrolysin (30 ml in 150 ml of physiologic solution during 4 weeks) preceded the same therapy with amiridin. The neuropsychological assessment was made according to Luria's method with a quantitative estimation of the regulatory and operational components of mental activity. Comparison of the results of neuropsychologic examination both before and after the therapy showed a more pronounced improvement in the states of all regulatory and separate operational components of mental activity in combined therapy with cerebrolysin and amiridin versus monotherapy with amiridin. In patients of group 2 with disturbances of higher mental functions the pathological symptomatology connected with anterior frontal and deep structures of brain was significantly decreased as compared with the patients from group 1.

Topics: Aged; Alzheimer Disease; Amino Acids; Aminoquinolines; Cholinesterase Inhibitors; Cognition Disorders; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Male; Neuroprotective Agents; Neuropsychological Tests; Nootropic Agents; Severity of Illness Index; Treatment Outcome

Cognitive functions were assessed in 116 patients, aged from 18 to 84 years, in the early rehabilitation period of the first ischemic stroke of hemispheric localization and in 44 patients with cerebrovascular disorders without history of stroke. MMSE, FAB, CDT, 5 words' test, the Schulte test, verbal fluency test, CES-D were administered. The statistically significant decrease in cognitive functions was seen in the index group compared with the control one. The level of cognitive impairment was correlated with the severity of neurological deficit and age and was aggravated by depression. Neuromidin (ipidacrinum) was used in the treatment of 31 patients in incremental doses (intramuscular injections of 10 mg/day during the first two weeks and later--60 mg/day during 40 days per os). As a result, the significant increase in cognitive function with the recovery of attention, memory and lobe functions was noted.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoquinolines; Attention; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Male; Memory; Middle Aged; Neuropsychological Tests; Stroke; Stroke Rehabilitation; Young Adult

Topics: Aminoquinolines; Brain Injuries; Cognition Disorders; Humans; Intercellular Signaling Peptides and Proteins; Nootropic Agents; Peptides; Piracetam

The aim of the present study was to assess the efficacy of combined administration of neuromidin and ovestin in low doses for pharmacocorrection of cognitive disorders in women after total ovariectomy. The obtained results are indicative of a pronounced efficacy of the proposed combined therapy for the pharmaco-correction of cognitive disorders as compared to the standard hormone replacement therapy in women with hypoestrogenic syndrome. This is confirmed by significant decrease of mental impairments on the conventional (Mattis dementia) clinical rating scale and in neuropsychological tests.

Topics: Adult; Aminoquinolines; Cognition Disorders; Estriol; Female; Humans; Middle Aged; Ovariectomy

Neuromidin (ipidacrin) was administered to 41 patients, aged 51-79 years, with mild cognitive impairment (MSI) (19) and vascular dementia (22). The drug was prescribed in increasing dosages from 10 to 40 mg during 6 months (a dosage of 40 mg was administered from the 4th week of the treatment). Cognitive functioning was assessed using some clinical scales (CGI, MMSE, GDS etc) and common neuropsychological tests at the base-line and on the 3rd and 6th month of the treatment. A statistically significant therapeutic effect of neuromidin was revealed in both types of cognitive disorders, with the maximal improvement on the first 3 months and further maintenance of the effect. The most distinct dynamics was observed for memory, attention, abstract reasoning, constructive abilities and general mental activity. The drug was well tolerated.

Topics: Aged; Aminoquinolines; Cognition; Cognition Disorders; Dementia, Vascular; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Memory; Middle Aged; Severity of Illness Index; Treatment Outcome

Acetylcholinesterase (AChE) activity and parameters of the system of regulation of lipid peroxidation (LPO) were estimated in blood of patients with Alzheimer's disease (AD) during therapy with amiridine and gliatiline. It was found that the therapy was accompanied by inhibition of AChE activity. A significant correlation was observed between clinical efficiency and changes of AChE activity. AD was characterised by essential changes in LPO parameters: the level of the primary products of oxidation was increased three times with a sharp increase (seven times) of total unsaturation of lipids. A significant correlation was found between AChE activity and the level of the primary products of oxidation in blood erythrocytes of AD patients before and after therapy with amiridine and gliatiline.

Topics: Aged; Alzheimer Disease; Aminoquinolines; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Severity of Illness Index